Pfizer Inc. (FRA:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 120.04B |
| Revenue (ttm) | 53.69B |
| Net Income (ttm) | 8.41B |
| Shares Out | n/a |
| EPS (ttm) | 1.48 |
| PE Ratio | 14.28 |
| Forward PE | 7.88 |
| Dividend | 1.53 (7.17%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 7,174 |
| Average Volume | 62,236 |
| Open | 21.14 |
| Previous Close | 20.78 |
| Day's Range | 21.06 - 21.66 |
| 52-Week Range | 18.57 - 26.54 |
| Beta | n/a |
| RSI | 51.53 |
| Earnings Date | Nov 4, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Markets exhale as Novo Nordisk withdraws from Metsera bidding war
Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s shares slipped but Novo Nordisk’s stock rose on news it was bowing out of th...
Metsera: Why Pfizer And Novo Nordisk Fought Hard Over This Obesity Drug Developer
Pfizer acquires Metsera, gaining cutting-edge obesity and diabetes therapies.
PFE a Top 25 Dividend Giant With $19.76B Held By ETFs
Pfizer Inc (Symbol: PFE) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $19.76B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a st...
Why a Strong Quarter Wasn't Enough to Send Shares of Pfizer Soaring
Pfizer not only beat expectations last quarter, but also boosted its guidance.
Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript
Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology - Slideshow
FDA Approves Generic Version of Pfizer's (PFE) Premarin Amid Label Changes
FDA Approves Generic Version of Pfizer's (PFE) Premarin Amid Label Changes
PFE: FDA Updates Hormone Replacement Therapy Warnings
PFE: FDA Updates Hormone Replacement Therapy Warnings
Pfizer Gets Metsera: Why The $20.65 CVR Is Highly Likely To Pay Out (In Part)
Notable ETF Inflow Detected - VYM, PFE, HON, BX
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected ...
Pfizer (PFE) Acquires Metsera (MTSR) for Over $10 Billion to Re-enter Obesity Drug Market
Pfizer (PFE) Acquires Metsera (MTSR) for Over $10 Billion to Re-enter Obesity Drug Market
Pfizer to buy Metsera in deal worth up to $10 billion
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted ...
Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial
Cogent Biosciences, Inc. (NASDAQ: COGT) stock is trading higher on Monday, with a session volume of 10.95 million compared to the average volume of 1.97 million as per data from Benzinga Pro . COGT i...
US stocks today: Markets rise on hopes of US govt shutdown ending; Nasdaq jumps over 440 points, S&P 500 gains 1%
Global stock markets surged on Monday. Investors are optimistic as the US government shutdown nears resolution after a 40-day standoff. A bipartisan deal to fund government operations has been reached...
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer's strategy for clinical de...
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company’s up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical de...
Watch CNBC's full interview with Pfizer CEO Albert Bourla
Pfizer CEO Albert Bourla joins 'Squawk on the Street' to discuss the company’s acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical development and ma...
Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion
Metsera stock toppled Monday after the buyout battle with Pfizer and Novo Nordisk ended. Pfizer will acquire Metsera for up to $10 billion.
Pre-Market Most Active for Nov 10, 2025 : IFRX, GREE, IPHA, TSLL, SQQQ, NVDA, PFE, BBAI, OSCR, IONQ, HLN, THS
The NASDAQ 100 Pre-Market Indicator is up 380.3 to 25,440.11. The total Pre-Market volume is currently 219,886,694 shares traded.The following are the most active stocks for the pre-market session: In...
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration.
Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.
Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.
The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.
Pfizer Clinches $10 Billion Deal for Metsera After Fierce Bidding War With Novo Nordisk
Pfizer Clinches $10 Billion Deal for Metsera After Fierce Bidding War With Novo Nordisk
Metsera (MTSR) Shares Nosedive After Pfizer Clinches Weight-Loss Biotech Deal
Metsera (MTSR) Shares Nosedive After Pfizer Clinches Weight-Loss Biotech Deal